Nutex Health Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

NUTX$194.16+7.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Equity (unaudited)

Common Stock · Additional Paid-inCapital · Retained Earnings (Accumulated Deficit) · NoncontrollingInterests · TotalEquity
(In thousands, except share data) · Shares · Amount
Balance at December 31, 2024	5,511,452	$6		$489,409		$(356,976)		$56,094		$188,533
Common stock issued for ESPP	1,161		—		40		—		—		40
Stock-based compensation	422,091		—		23,252		—		—		23,252
Vesting of Restricted Stock Units	15,835	—		—		—		—		—
Distributions	—	—		—		—		(7,364)		(7,364)
Net income	—	—		—		21,217		29,589		50,806
Balance at March 31, 2025	5,950,539	$6		$512,701		$(335,759)		$78,319		$255,267
Common stock issued for ESPP	866		—		65		—		—		65
Asset acquisition noncontrolling interest	—	—		—		—		789		789
Debt conversion to common stock	17,874	—		477		—		—		477
Stock-based compensation	602,798	1		75,304		—		—		75,305
Vesting of Restricted Stock Units	23,032	—		—		—		—		—
Contributions	—	—		152		—		90		242
Distributions	—	—		—		—		(11,412)		(11,412)
Net income	—	—		—		(17,697)		33,841		16,144
Balance at June 30, 2025	6,595,109	$7		$588,699		$(353,456)		$101,627		$336,877
Common stock issued for ESPP	351		—		42		—		—		42
Common stock issued for acquisition	2,102	—		250		—		—		250
Asset acquisition noncontrolling interest	—	—		—		—		1,200		1,200
Stock-based compensation	307,700	—		26,189		—		—		26,189
Contributions	—	—		—		—		74		74
Distributions	—	—		—		—		(23,398)		(23,398)
Net income	—	—		—		55,435		41,364		96,799
Balance at September 30, 2025	6,905,262	$7		$615,180		$(298,021)		$120,867		$438,033

Balance at December 31, 2025	7,086,670	$7		$615,627		$(286,187)		$93,990	$423,437
Common stock issued for ESPP	547	—	97		—		—	97
Vesting of Restricted Stock Units	52,096	—	—		—		—	—
Stock-based compensation	12,753	—	1,604		—		—	1,604
Stock repurchases and retirements	(200,444)	—	(31,730)		—		—	(31,730)
Contributions	—	—	68		—		1,171	1,239
Distributions	—	—	—		—		(15,357)	(15,357)
Net income	—	—	—		46,807		15,956	62,763
Balance at March 31, 2026	6,951,622	$7		$585,666		$(239,380)		$95,760	$442,053
Warrant exercises	2,500	—	75		—		—	75
Common stock issued for ESPP	1,962	—	197		—		—	197
Stock-based compensation	—	—	724		—		—	724
Stock repurchases and retirements	(112,299)	—	(18,957)		—		—	(18,957)
Contributions	—	—	142		—		24	166
Distributions	—	—	—		—		(13,263)	(13,263)
Net income	—	—	—		65,842		30,475	96,317
Balance at June 30, 2026	6,843,785	$7		$567,847		$(173,538)		$112,996	$507,312
Warrant exercises	10,364	—	175		—		—	175
Common stock issued for ESPP	943	—	183		—		—	183
Stock-based compensation	—	—	665		—		—	665
Vesting of Restricted Stock Units	2,412	—	—		—		—	—
Contributions	—	—	—		—		320	320
Distributions	—	—	—		—		(25,088)	(25,088)
Net income	—	—	—		40,229		17,114	57,343
Balance at September 30, 2026	6,857,504	$7		$568,870		$(133,309)		$105,342	$540,910

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.